10月9日，和元生物涨4.19%，成交额2.85亿元。两融数据显示，当日和元生物获融资买入额2519.41万 元，融资偿还2792.02万元，融资净买入-272.62万元。截至10月9日，和元生物融资融券余额合计1.53亿 元。 截至6月30日，和元生物股东户数1.26万，较上期增加6.83%；人均流通股50864股，较上期减少6.39%。 2025年1月-6月，和元生物实现营业收入1.20亿元，同比增长6.01%；归母净利润-1.05亿元，同比增长 7.74%。 责任编辑：小浪快报 融资方面，和元生物当日融资买入2519.41万元。当前融资余额1.53亿元，占流通市值的2.90%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，和元生物10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 资料显示，和元生物技术(上海)股份有限公司位于上海市浦东新区紫萍路908弄19号楼，成立日期2013 年3月5日，上市日期2022年3月22日，公司主营业务涉及为基因治疗的基础研究提供基因治疗载体研 ...

责任编辑：小浪快报 资料显示，和元生物技术(上海)股份有限公司位于上海市浦东新区紫萍路908弄19号楼，成立日期2013 年3月5日，上市日期2022年3月22日，公司主营业务涉及为基因治疗的基础研究提供基因治疗载体研 制、基因功能研究等CRO服务,以及为基因药物的研发提供IND-CMC药学研究、临床样品GMP生产等 CDMO服务。主营业务收入构成为：细胞和基因治疗CDMO服务54.75%，细胞和基因治疗CRO服务 33.96%，生物制剂、试剂及其他10.28%，再生医学服务1.02%。 截至6月30日，和元生物股东户数1.26万，较上期增加6.83%；人均流通股50864股，较上期减少6.39%。 2025年1月-6月，和元生物实现营业收入1.20亿元，同比增长6.01%；归母净利润-1.05亿元，同比增长 7.74%。 9月25日，和元生物跌1.84%，成交额1.67亿元。两融数据显示，当日和元生物获融资买入额1909.92万 元，融资偿还2313.76万元，融资净买入-403.83万元。截至9月25日，和元生物融资融券余额合计1.44亿 元。 融资方面，和元生物当日融资买入1909.92万元。当前融资余 ...

Core Viewpoint - The company is facing challenges in its cell and gene therapy CDMO business due to macroeconomic changes, industry conditions, and downstream demand, resulting in low order prices and negative gross margins, although there has been some improvement compared to the previous year [1][2]. Group 1: Company Overview - The company is focused on cell and gene therapy, which is a key development direction in the biopharmaceutical industry, supported by national and local policies [2]. - The company aims to enhance its competitiveness and market penetration by improving R&D efficiency, expanding into new business areas, and optimizing operations [2]. Group 2: Financial Data - The company reported a net loss of RMB 10,515.07 million for the first half of 2025, primarily due to low order prices and the early production stage of its projects [21]. - The company has fully utilized the raised funds for planned investments, with no reported issues in fund management or usage [10][20]. Group 3: Shareholder Information - The company has not disclosed any special arrangements regarding corporate governance or significant changes in major shareholders [3][4]. Group 4: Upcoming Events - The company will hold a performance briefing on August 27, 2025, to discuss its half-year results and address investor questions [5][8].

Core Viewpoint - He Yuan Bio disclosed a research meeting with investors, highlighting its focus on domestic clients and the growth in the cell and gene therapy sector despite challenges in the broader healthcare financing landscape [1][2]. Company Overview - He Yuan Bio hosted an event titled "I am a Shareholder - Walk into the Listed Company" on July 18, 2025, attended by over 10 investors [2]. - The company is led by key personnel including Chairman and General Manager Pan Oudong, and other executives participated in the discussions [1]. Financial Performance - In 2024, the company achieved revenue of 248.15 million yuan, a year-on-year increase of 21.16%, with specific growth in CRO and CDMO segments [4]. - For Q1 2025, revenue was 52.85 million yuan, a decline of 11.29% compared to the previous year, primarily due to a drop in CDMO revenue [4]. Client Distribution - The company primarily serves domestic clients, with plans to expand its CRO services to pharmaceutical enterprises and enhance its international presence in the CDMO sector [3]. Data Security Measures - He Yuan Bio emphasizes data security, having achieved ISO27001 certification and implementing robust data management and protection systems [5]. CDMO Dependency - The company noted that the complexity of new drug development increases reliance on CDMO services, with over 65% of gene therapy companies outsourcing production [6]. Competitive Advantages - He Yuan Bio possesses a comprehensive CRO/CDMO technology platform, advanced GMP production facilities, and a strong project management capability, which collectively enhance its competitive edge in the cell and gene therapy market [6][7][8]. Cash Flow Situation - In 2024, the company reported a net cash flow of -218.09 million yuan, with ongoing challenges in cash flow due to extended payment cycles from clients [9]. - As of Q1 2025, the company continued to experience negative cash flow but anticipates improvement with the recovery of the investment environment [9]. Accounts Receivable and Bad Debt - As of December 31, 2024, the company had accounts receivable of 85 million yuan, with a bad debt provision of 6.96 million yuan, indicating a low risk of bad debts due to a strong client base [9]. Market Trends - In H1 2025, global healthcare financing decreased by 10%, while financing in China's cell and gene therapy sector increased to approximately 409 million USD, reflecting a recovery in this niche market [9].

Core Viewpoint - The company has developed a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2025, aimed at enhancing operational quality and efficiency while safeguarding investor rights and promoting sustainable development [1][12]. Group 1: Business Focus and Core Competitiveness - The company focuses on cell and gene therapy technology services, providing CRO services for basic research and CDMO services for drug development [1][2]. - The company aims to ensure steady growth in its existing CRO business while exploring new business opportunities and technologies to enhance profitability [2][3]. - In the CDMO sector, the company plans to leverage its production capacity and technical advantages to support clinical projects and attract more orders [3][4]. Group 2: Investor Returns and Shareholder Rights - The company emphasizes investor returns and has decided not to distribute dividends for 2024 due to operating losses, prioritizing financial stability and long-term shareholder interests [8][9]. - A share buyback plan will be implemented to enhance shareholder value and market recognition [9][10]. Group 3: Information Disclosure and Investor Communication - The company prioritizes high-quality information disclosure and has established multiple channels for investor communication, including performance briefings and online platforms [10][11]. - Efforts will be made to improve transparency and respond to market concerns, ensuring investors are well-informed about the company's operations and strategies [11][12]. Group 4: Governance and Sustainable Development - The company is committed to enhancing its governance structure and compliance with legal regulations, focusing on sustainable development and ESG initiatives [11][12]. - A robust governance framework will be maintained to ensure effective oversight and decision-making, benefiting both the company and its shareholders [12][13].

Core Insights - The company reported a revenue of 248 million yuan for 2024, marking a year-on-year growth of 21.16% [1] - The establishment of the "Regenerative Medicine Center" signifies a strategic expansion into cell therapy, potentially becoming a new growth highlight for the company [1] - The completion of the first phase of the Lingang Industrial Base enhances the company's production capabilities, positioning it as a leading provider of one-stop services for cell and gene therapy product development [1] Financial Performance - The company achieved CDMO sales revenue of 135 million yuan, an increase of 26.12% compared to the previous year [2] - New CDMO business orders exceeded 270 million yuan during the year, indicating strong demand and order progress [2] - The company assisted clients in obtaining 12 IND approvals within the reporting period, contributing to a total of 44 IND approvals to date [2] Strategic Initiatives - The company initiated a share repurchase plan in 2025, having repurchased approximately 18.73 million shares, accounting for 2.8853% of total shares, with an average price of 5.34 yuan per share [2] - Part of the repurchased shares is intended for equity incentives, aiming to align the interests of the core team with the company's long-term development [2] - The company continues to leverage its diverse technical capabilities across various cell therapy fields, including oncolytic viruses, AAV gene therapy, CAR-T/NK, and stem cells [2]